The purpose of this study was to determine the effect of vertical whole-body vibration (WBV) on heart rate (HR), mean arterial pressure (MAP), femoral artery blood flow (FBF), and leg skin temperature (LSk(temp)) during static exercise. These parameters were examined: seated next to the WBV device (passive, unloaded), with feet secured onto the WBV platform (knees 90 degrees flexion) and while standing in a semi-squat position (static, loaded, knees 120 degrees flexion); both with and without WBV. Conditions involved 1 min bouts separated by 1 min rest, repeated 15 times followed by 10 min recovery. WBV in the seated condition had no effect on the responses examined. The static semi-squat without WBV increased MAP 9 mmHg (P < 0.05) with no significant effect on HR, FBF, or LSk(temp). Similarly, WBV static semi-squat increased MAP 8-14 mmHg (P < 0.05), FBF 135-180 mL/min, and LSk(temp) 1.8-3.1 degrees C (P < 0.05). However, only the LSk(temp) was increased above the no-WBV semi-squat position (P < 0.05). The addition of WBV to repeated intermittent static semi-squats does not appear to be a significant cardiovascular stressor.

Purpose: To overcome the discrepancy between evidence-based guidelines and practice for osteoarthritis (OA), the Swedish national program "Better management of patients with osteoarthritis" (BOA) was initiated in 2008 to offer all patients with hip and knee OA information and an individually adapted exercise program in accordance to international guidelines for OA. The purpose of this study was to evaluate the outcomes of the BOA program from 2008 to 2016 stratified by hip or knee, using data from the national quality register, the BOA register. Methods: This is a registry-based study with data from patients with knee and hip OA who participated in the BOA program, i.e. education and individually adapted exercise delivered by trained physiotherapists and occupational therapists. Outcomes were evaluated at baseline as well as after 3 and 12 months, and include pain intensity (0 to 10, where 0 is no pain and 10 is the worst imaginable pain), quality of life (EQ-5D-5L), pain self-efficacy (ASES-pain), other symptoms self-efficacy (ASESother), pain frequency (never, every month, every week, every day or all the time), use of painkillers (yes/no), willingness to undergo surgery caused by ailments from knee or hip (yes/no), fear of movement (yes/ no), sick leave due to knee or hip problems (yes/no). The analyses of pain intensity, quality of life and self-efficacy were conducted using General Linear Model (repeated measurement) between baseline and 3 months; or baseline and 12 months. The analysis was adjusted for joint, sex, age and BMI. McNemar's test was used to assess differences in the pain frequency, number of patients taking painkillers, number of patients' desire surgery, fear of movement and sick leave. Results: For this study 46935 patients with knee (n¼ 30682) and hip OA (n¼16353) were included. Patients with knee OA experienced a decrease in pain intensity of 1.18 points (95% CI; 1.15 to 1.2) and 0.92 points (95% CI; 0.89 to 0.95) at 3 and 12 months respectively while patients with hip OA experienced a decrease in pain intensity of 0.83 points (95% CI; 0.8 to 0.87) and 0.46 points (0.42 to 0.51) at 3 and 12 months respectively. Patients with knee OA experienced an increased Quality of life by 0.065 points (95% CI; 0.063 to 0.068) and 0.039 (95% CI; 0.036 to 0.042) at 3 and 12 months respectively while patients with hip OA experienced an increased Quality of life by 0.04 (95% CI; 0.04 to 0.05) and 0.009 (95% CI; 0.004 to 0.014) at 3 and 12 months respectively. Patients with knee OA experienced an increased Self-efficacy/pain by 4.7 points (95% CI; 4.5 to 4.95) at 3 month but the Self-efficacy/pain decreased by -0.9 (95% CI; -1.2 to -0.6) at 12 months while patients with hip OA experienced an increased Self-efficacy/other by 3.1 (95% CI; 2.8 to 3.4) at 3 month but the Self-efficacy/pain decreased by -3.6 (95% CI; -4.1 to -3.1) at 12 months. Patients with knee OA experienced an increased Self-efficacy/other by 4.1 points (95% CI; 3.9 to 4.3) at 3 month but the Self-efficacy/other decreased by -0.8 (95% CI; -1,...

No abstract

No abstract

No abstract